PMA device
Guardian 4 Sensor
Medtronic Minimed, Inc. · Sensor, Glucose, Invasive, Component Of Automated Insulin Delivery System (SFI, Class III) · First FDA decision Oct 9, 2025, newest Oct 9, 2025Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
26
Naming "Guardian 4"
MAUDE reports
115
Brand "Guardian 4", since 2015
PubMed studies
28
Mentioning "Guardian 4"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Guardian 4 Sensor
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Guardian 4 SensorPMA supplement
P250012-S002 · Decided Oct 9, 2025 · 55 days after receipt · Normal 180 Day Track No User Fee
Device type: Sensor, Glucose, Invasive, Component of automated insulin delivery system (SFI) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Guardian 4", any status and sponsor, newest update first.
- Interventional Clinical Trial Evaluating COVER PATCH CAPTEUR PROTECT Support Solutions for Continuous Glucose Monitoring Sensors in Patients With DiabetesPivotal-lookingRecruiting
CAPTEUR PROTECTNot on our public-company list
NCT07018180 · 194 participants (planned) · Start Dec 5, 2025
Device: Use of COVER patchs for continuous glucose monitoring sensor · For: Diabetes
Sites: Bron, France; Corbeil-Essonnes, France; Grenoble, France · 10 sites in all
University of NebraskaAcademic, hospital or other
NCT05275543 · 51 participants · Start Apr 1, 2022 · Primary completion Jan 3, 2025
Device: Paro Robot · For: Pediatric ALL; Child, Hospitalized; Physical Therapy Modalities and 2 more
Sites: Omaha, Nebraska
Ann & Robert H Lurie Children's Hospital of ChicagoAcademic, hospital or other
NCT05823090 · 9 participants · Start Dec 21, 2021 · Primary completion Nov 8, 2022
Device: light box (Carex DayLight Classic Model) · For: Depression; Adolescent - Emotional Problem
Sites: Chicago, Illinois
23 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Guardian 4", and for the whole product code for context.
This brand
115 reports: 66 malfunction, 48 injury, 1 death
Whole product code SFI
5,905 reports: 5,762 malfunction, 143 injury, 0 death
Newest reports for this brand
- Medtronic Guardian 4 TransmitterMalfunction
MW6002104 · Received Sep 10, 2026 · Event dated Sep 3, 2026
Device type: Automated Insulin Dosing Device System, Single Hormonal Control (OZP)
Device problem as coded: Premature Discharge of Battery
Patient problem as coded: Elevated Ketones/ Diabetic Ketoacidosis
- Medtronic Guardian 4 TransmitterMalfunction
MW6002105 · Received Sep 10, 2026 · Event dated Sep 3, 2026
Device type: Automated Insulin Dosing Device System, Single Hormonal Control (OZP)
Device problem as coded: Premature Discharge of Battery
Patient problem as coded: Elevated Ketones/ Diabetic Ketoacidosis
- MEDTRONIC GUARDIAN 4 SENSORMalfunction
MW5190828 · Received Jul 20, 2026 · Event dated Jul 9, 2026
Device type: Sensor, Glucose, Invasive, Component Of Automated Insulin Delivery System (SFI)
Device problem as coded: Incorrect, Inadequate or Imprecise Result or Readings; Failure to Sense; Failure to Calibrate; Output below Specifications
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Guardian 4"[tiab]. The summary above synthesizes these.
- Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases.
Almurashi AM, Rodriguez E, Garg SK · J Indian Inst Sci · 2023Review
- Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems.
Forlenza GP, Dai Z, Niu F, et al. · Diabetes Technol Ther · 2024
- Comparison of Metabolic Control in Children and Adolescents Treated with Insulin Pumps.
Lejk A, Myśliwiec K, Michalak A, et al. · Children (Basel) · 2024
- One-Year Follow-Up of Advanced Hybrid Closed-Loop System in Adults with Type 1 Diabetes Previously Naive to Diabetes Technology: The Effect of Switching to a Calibration-Free Sensor.
Matejko B, Juza A, Kiek-Wilk B, et al. · Diabetes Technol Ther · 2023Research Support, Non-U.S. Gov't
- In Silico Evaluation of the Medtronic 780G System While Using the GS3 and Its Calibration-Free Successor, the G4S Sensor.
Grosman B, Parikh N, Roy A, et al. · Ann Biomed Eng · 2023
- Guardian 4-Associated Contact Dermatitis in a Teenager With Multiple Sensitizations.
Guimarães J, Marcelino J, Silva L, et al. · Dermatitis · 2026
- Consistent efficacy and safety of automated insulin delivery in children aged 2-6 years: results from the LENNY trial continuation phase.
Dovc K, Tuomaala A, Kuusela S, et al. · Diabetes Res Clin Pract · 2025Randomized Controlled Trial, Equivalence Trial
- Factory-Calibrated Continuous Glucose Monitoring Systems in Type 1 Diabetes: Accuracy during In-Clinic Exercise and Home Use.
Lundemose SB, Laugesen C, Ranjan AG, et al. · Sensors (Basel) · 2023
- The Feasibility of an Experimental Hypobaric Simulation to Evaluate the Safety of Closed-Loop Insulin Delivery Systems in Flight-Related Atmospheric Pressure Changes.
Fan KS, Shojaee-Moradie F, Manoli A, et al. · Diabetes Technol Ther · 2025Research Support, Non-U.S. Gov't
- Long-term assessment of the NHS hybrid closed-loop real-world study on glycaemic outcomes, time-in-range, and quality of life in children and young people with type 1 diabetes.
Ng SM, Wright NP, Yardley D, et al. · BMC Med · 2024Research Support, Non-U.S. Gov't
- Early Real-World Performance of the MiniMedࡊ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States.
Thrasher JR, Arrieta A, Niu F, et al. · Diabetes Technol Ther · 2024
- Glycemic Outcomes During Early Use of the MiniMedࡊ 780G Advanced Hybrid Closed-Loop System with Guardianࡊ 4 Sensor.
Cordero TL, Dai Z, Arrieta A, et al. · Diabetes Technol Ther · 2023Clinical Trial, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code SFI.
- Simplera Sync Sensor, Guardian 4 SensorMedtronic Minimed, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.